Logo image of CYBE

CYBEROPTICS CORP (CYBE) Stock Fundamental Analysis

NASDAQ:CYBE - Nasdaq - US2325171021 - Common Stock - Currency: USD

54  0 (0%)

After market: 53.99 -0.01 (-0.02%)

Fundamental Rating

4

Taking everything into account, CYBE scores 4 out of 10 in our fundamental rating. CYBE was compared to 109 industry peers in the Semiconductors & Semiconductor Equipment industry. While CYBE has a great health rating, there are worries on its profitability. CYBE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYBE was profitable.
CYBE had a positive operating cash flow in the past year.
CYBE Yearly Net Income VS EBIT VS OCF VS FCFCYBE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 5M 10M

1.2 Ratios

Industry RankSector Rank
ROA 15.04%
ROE 18.59%
ROIC 17.86%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYBE Yearly ROA, ROE, ROICCYBE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 5 -5 10 15 20

1.3 Margins

CYBE's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of CYBE has grown nicely.
Industry RankSector Rank
OM 17.6%
PM (TTM) 15.92%
GM N/A
OM growth 3Y43.85%
OM growth 5Y10.73%
PM growth 3Y46.48%
PM growth 5Y-4.66%
GM growth 3YN/A
GM growth 5YN/A
CYBE Yearly Profit, Operating, Gross MarginsCYBE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 10 20 30 40

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CYBE is still creating some value.
Compared to 1 year ago, CYBE has more shares outstanding
There is no outstanding debt for CYBE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYBE Yearly Shares OutstandingCYBE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M
CYBE Yearly Total Debt VS Total AssetsCYBE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 14.55 indicates that CYBE is not in any danger for bankruptcy at the moment.
CYBE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 14.55
ROIC/WACC1.57
WACC11.35%
CYBE Yearly LT Debt VS Equity VS FCFCYBE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M 40M 60M

2.3 Liquidity

CYBE has a Current Ratio of 4.45. This indicates that CYBE is financially healthy and has no problem in meeting its short term obligations.
CYBE has a Quick Ratio of 2.83. This indicates that CYBE is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.45
Quick Ratio 2.83
CYBE Yearly Current Assets VS Current LiabilitesCYBE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

CYBE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 104.81%, which is quite impressive.
CYBE shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.63% yearly.
Looking at the last year, CYBE shows a very strong growth in Revenue. The Revenue has grown by 26.08%.
Measured over the past years, CYBE shows a small growth in Revenue. The Revenue has been growing by 6.97% on average per year.
EPS 1Y (TTM)104.81%
EPS 3Y62.71%
EPS 5Y0.63%
EPS Q2Q%41.46%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y12.75%
Revenue growth 5Y6.97%
Sales Q2Q%9.38%

3.2 Future

The Earnings Per Share is expected to grow by 24.37% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.27% on average over the next years. This is quite good.
EPS Next Y21.43%
EPS Next 2Y21.71%
EPS Next 3Y23.07%
EPS Next 5Y24.37%
Revenue Next Year14.47%
Revenue Next 2Y12.8%
Revenue Next 3Y10.34%
Revenue Next 5Y8.27%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CYBE Yearly Revenue VS EstimatesCYBE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CYBE Yearly EPS VS EstimatesCYBE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 25.35, which means the current valuation is very expensive for CYBE.
CYBE's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.29.
The Price/Forward Earnings ratio is 21.70, which indicates a rather expensive current valuation of CYBE.
CYBE is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.08, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.35
Fwd PE 21.7
CYBE Price Earnings VS Forward Price EarningsCYBE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF 72.18
EV/EBITDA 18.73
CYBE Per share dataCYBE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as CYBE's earnings are expected to grow with 23.07% in the coming years.
PEG (NY)1.18
PEG (5Y)40.42
EPS Next 2Y21.71%
EPS Next 3Y23.07%

More info and screens

0

5. Dividend

5.1 Amount

CYBE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYBEROPTICS CORP

NASDAQ:CYBE (11/3/2022, 8:24:29 PM)

After market: 53.99 -0.01 (-0.02%)

54

0 (0%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)07-27 2022-07-27/amc
Earnings (Next)11-22 2022-11-22/amc
Inst Owners0.4%
Inst Owner Change0%
Ins Owners0.51%
Ins Owner Change0%
Market Cap401.02M
Analysts43.33
Price Target55.08 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.08%
Min EPS beat(2)23.61%
Max EPS beat(2)24.54%
EPS beat(4)4
Avg EPS beat(4)43.25%
Min EPS beat(4)23.61%
Max EPS beat(4)80.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.67%
Min Revenue beat(2)3.35%
Max Revenue beat(2)5.99%
Revenue beat(4)4
Avg Revenue beat(4)3.97%
Min Revenue beat(4)2.82%
Max Revenue beat(4)5.99%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 25.35
Fwd PE 21.7
P/S 3.94
P/FCF 72.18
P/OCF 54.77
P/B 4.61
P/tB 4.69
EV/EBITDA 18.73
EPS(TTM)2.13
EY3.94%
EPS(NY)2.49
Fwd EY4.61%
FCF(TTM)0.75
FCFY1.39%
OCF(TTM)0.99
OCFY1.83%
SpS13.69
BVpS11.72
TBVpS11.51
PEG (NY)1.18
PEG (5Y)40.42
Profitability
Industry RankSector Rank
ROA 15.04%
ROE 18.59%
ROCE N/A
ROIC 17.86%
ROICexc N/A
ROICexgc 18.2%
OM 17.6%
PM (TTM) 15.92%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y43.32%
ROICexcg growth 5Y6.67%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y43.85%
OM growth 5Y10.73%
PM growth 3Y46.48%
PM growth 5Y-4.66%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 73.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 34.34%
Current Ratio 4.45
Quick Ratio 2.83
Altman-Z 14.55
F-Score7
WACC11.35%
ROIC/WACC1.57
Cap/Depr(3y)63.62%
Cap/Depr(5y)66.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)75.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.81%
EPS 3Y62.71%
EPS 5Y0.63%
EPS Q2Q%41.46%
EPS Next Y21.43%
EPS Next 2Y21.71%
EPS Next 3Y23.07%
EPS Next 5Y24.37%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y12.75%
Revenue growth 5Y6.97%
Sales Q2Q%9.38%
Revenue Next Year14.47%
Revenue Next 2Y12.8%
Revenue Next 3Y10.34%
Revenue Next 5Y8.27%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.65%
FCF growth 3Y59.57%
FCF growth 5Y1.31%
OCF growth 1Y80.34%
OCF growth 3Y35.01%
OCF growth 5Y2.04%